Knockdown of spindle pole body component 25 homolog inhibits cell proliferation and cycle progression in prostate cancer

Cui,Feilun; Hu,Jianpeng; Fan,Yu; Tan,Jian; Tang,Huaming

doi:10.3892/ol.2018.8003

Knockdown of spindle pole body component 25 homolog inhibits cell proliferation and cycle progression in prostate cancer

Authors:
- Feilun Cui
- Jianpeng Hu
- Yu Fan
- Jian Tan
- Huaming Tang
View Affiliations

Affiliations: Department of Urology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu 212000, P.R. China, Department of Oncology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu 212000, P.R. China
Published online on: February 8, 2018 https://doi.org/10.3892/ol.2018.8003
Pages: 5712-5720
Copyright: © Cui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer (PCa) is the most frequently diagnosed type of cancer in Chinese males. Cell‑cycle aberration is a hallmark of cancer. Spindle pole body component 25 homolog (SPC25), a component of the Ndc80 complex, serves an important role in regulating mitotic chromosome segregation. However, the functional roles of SPC25 in PCa remain poorly understood. To the best of our knowledge, the present study was the first to demonstrate that SPC25 is significantly upregulated in PCa. In order to investigate the molecular roles of SPC25, a loss of function assay was performed, revealing that SPC25 knockdown inhibited cell proliferation, and induced a decrease in the number of cells in the S phase and an increase in the number of cells in the G2/M phase. Furthermore, SPC25 knockdown promoted the apoptosis of PCa cells. Additionally, bioinformatics analysis revealed multiple functional roles of SPC25 in regulating cell proliferation, apoptosis, invasion, transforming growth factor‑β signaling and the SUMOylation pathway in PCa. The present study also evaluated the potential prognostic value of SPC25 using The Cancer Genome Atlas RNA‑seq data and demonstrated that SPC25 was upregulated in late stage PCa. Kaplan‑Meier analysis demonstrated that lower SPC25 expression was associated with an improved survival rate in patients with PCa. Taken together, these results suggested that SPC25 serves an oncogenic role in PCa and may act as a novel diagnostic and therapeutic target for PCa.

View Figures

View References

1	Dominguez-Brauer C, Thu KL, Mason JM, Blaser H, Bray MR and Mak TW: Targeting mitosis in cancer: Emerging strategies. Mol Cell. 60:524–536. 2015. View Article : Google Scholar : PubMed/NCBI
2	DeLuca JG, Gall WE, Ciferri C, Cimini D, Musacchio A and Salmon ED: Kinetochore microtubule dynamics and attachment stability are regulated by Hec1. Cell. 127:969–982. 2006. View Article : Google Scholar : PubMed/NCBI
3	Ciferri C, Pasqualato S, Screpanti E, Varetti G, Santaguida S, Dos Reis G, Maiolica A, Polka J, De Luca JG, De Wulf P, et al: Implications for kinetochore-microtubule attachment from the structure of an engineered Ndc80 complex. Cell. 133:427–439. 2008. View Article : Google Scholar : PubMed/NCBI
4	Tooley J and Stukenberg PT: The Ndc80 complex: Integrating the kinetochore's many movements. Chromosome Res. 19:377–391. 2011. View Article : Google Scholar : PubMed/NCBI
5	Hu P, Chen X, Sun J, Bie P and Zhang LD: siRNA-mediated knockdown against NUF2 suppresses pancreatic cancer proliferation in vitro and in vivo. Biosci Rep. 35(pii): e001702015.PubMed/NCBI
6	Fu HL and Shao L: Silencing of NUF2 inhibits proliferation of human osteosarcoma Saos-2 cells. Eur Rev Med Pharmacol Sci. 20:1071–1079. 2016.PubMed/NCBI
7	Xing XK, Wu HY, Chen HL and Feng HG: NDC80 promotes proliferation and metastasis of colon cancer cells. Genet Mol Res. 15:2016. View Article : Google Scholar
8	Suzuki A, Badger BL, Haase J, Ohashi T, Erickson HP, Salmon ED and Bloom K: How the kinetochore couples microtubule force and centromere stretch to move chromosomes. Nat Cell Biol. 18:382–392. 2016. View Article : Google Scholar : PubMed/NCBI
9	Wan X, Huang W, Yang S, Zhang Y, Pu H, Fu F, Huang Y, Wu H, Li T and Li Y: Identification of androgen-responsive lncRNAs as diagnostic and prognostic markers for prostate cancer. Oncotarget. 7:60503–60518. 2016. View Article : Google Scholar : PubMed/NCBI
10	Chang KH, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, Vessella R, Nelson PS, Kapur P, Guo X, et al: A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell. 154:1074–1084. 2013. View Article : Google Scholar : PubMed/NCBI
11	Zhang P, Gao K, Tang Y, Jin X, An J, Yu H, Wang H, Zhang Y, Wang D, Huang H, et al: Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants. Hum Mutat. 35:1142–1151. 2014. View Article : Google Scholar : PubMed/NCBI
12	An J, Ren S, Murphy SJ, Dalangood S, Chang C, Pang X, Cui Y, Wang L, Pan Y, Zhang X, et al: Truncated ERG oncoproteins from TMPRSS2-ERG fusions Are resistant to SPOP-mediated proteasome degradation. Mol Cell. 59:904–916. 2015. View Article : Google Scholar : PubMed/NCBI
13	Zhang L, Wang J, Wang Y, Zhang Y, Castro P, Shao L, Sreekumar A, Putluri N, Guha N, Deepak S, et al: MNX1 Is oncogenically upregulated in African-American prostate cancer. Cancer Res. 76:6290–6298. 2016. View Article : Google Scholar : PubMed/NCBI
14	Das M: MNX1: A novel prostate cancer oncogene. Lancet Oncol. 17:e5212016. View Article : Google Scholar : PubMed/NCBI
15	Xie JJ, Zhuo YJ, Zheng Y, Mo RJ, Liu ZZ, Li BW, Cai ZD, Zhu XJ, Liang YX, He HC and Zhong WD: High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer. Int Urol Nephrol. 49:817–823. 2017. View Article : Google Scholar : PubMed/NCBI
16	Schlomm T: Re: The molecular taxonomy of primary prostate cancer. Eur Urol. 69:11572016. View Article : Google Scholar : PubMed/NCBI
17	Cancer Genome Atlas Research Network, . The molecular taxonomy of primary prostate cancer. Cell. 163:1011–1025. 2015. View Article : Google Scholar : PubMed/NCBI
18	Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB, Kattan MW and Lin DW: Prostate cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 67:245–253. 2017. View Article : Google Scholar : PubMed/NCBI
19	Rees MA, Resnick MI and Oesterling JE: Use of prostate-specific antigen, Gleason score, and digital rectal examination in staging patients with newly diagnosed prostate cancer. Urol Clin North Am. 24:379–388. 1997. View Article : Google Scholar : PubMed/NCBI
20	Dirks WG and Drexler HG: STR DNA typing of human cell lines: Detection of intra- and interspecies cross-contamination. Methods Mol Biol. 946:27–38. 2013. View Article : Google Scholar : PubMed/NCBI
21	Nabzdyk CS, Chun M, Pradhan Nabzdyk L, Yoshida S and LoGerfo FW: Differential susceptibility of human primary aortic and coronary artery vascular cells to RNA interference. Biochem Biophys Res Commun. 425:261–265. 2012. View Article : Google Scholar : PubMed/NCBI
22	Tusher VG, Tibshirani R and Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 98:pp. 5116–5121. 2001; View Article : Google Scholar : PubMed/NCBI
23	Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al: Integrative genomic profiling of human prostate cancer. Cancer Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
24	Yin H, Meng T, Zhou L, Chen H and Song D: SPC24 is critical for anaplastic thyroid cancer progression. Oncotarget. 8:21884–21891. 2017.PubMed/NCBI
25	Pathania R, Ramachandran S, Mariappan G, Thakur P, Shi H, Choi JH, Manicassamy S, Kolhe R, Prasad PD, Sharma S, et al: Combined Inhibition of DNMT and HDAC blocks the tumorigenicity of cancer stem-like cells and attenuates mammary tumor growth. Cancer Res. 76:3224–3235. 2016. View Article : Google Scholar : PubMed/NCBI
26	Tsaur I, Hennenlotter J, Oppermann E, Munz M, Kuehs U, Stenzl A and Schilling D: PCA3 and PSA gene activity correlates with the true tumor cell burden in prostate cancer lymph node metastases. Cancer Biomark. 15:311–316. 2015. View Article : Google Scholar : PubMed/NCBI
27	Prensner JR, Rubin MA, Wei JT and Chinnaiyan AM: Beyond PSA: The next generation of prostate cancer biomarkers. Sci Transl Med. 4:127rv32012. View Article : Google Scholar : PubMed/NCBI
28	Wan X, Yang S, Huang W, Wu D, Chen H, Wu M, Li J, Li T and Li Y: UHRF1 overexpression is involved in cell proliferation and biochemical recurrence in prostate cancer after radical prostatectomy. J Exp Clin Canc Res. 35:342016. View Article : Google Scholar
29	D'Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen M, Art M, Tomaszewski JE and Wein A: Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology. 55:572–577. 2000. View Article : Google Scholar : PubMed/NCBI